Burning Rock Biotech Limited American Depositary Shares

Wuhan Ammunition Life-tech Co. Ltd., a Chinese cancer screening company, is making a second attempt to list on the Hong Kong Stock Exchange amid a cooling biotech market. Despite doubling revenues to 15.42 million yuan in 2025, the company's net losses widened 26.8% and it faces a challenging valuation of 147x price-to-sales ratio. The sector has...

Burning Rock Biotech Limited (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on December 22, 2025 were approved. The resolutions included ratifying Ernst & Young Hua Ming LLP as auditor, re-electing directors Feng Deng and Licen Lisa Xu, and authorizing directors to implement the resolutions.

Burning Rock Biotech reported Q3 2025 financial results with total revenues of RMB 131.6 million, a slight 2.3% increase from the same period in 2024. The company saw decreased revenues in in-hospital and central laboratory channels but significant growth in pharma research and development services. Net loss was RMB 16.8 million, an improvement f...

Burning Rock and Riken Genesis received approval in Japan for a companion diagnostic system to guide treatment decisions for hormone-receptor-positive breast cancer patients using capivasertib.

Burning Rock Biotech reported Q2 2025 revenues of RMB148.5 million, a 9.6% increase from the same period in 2024. The company reduced operating expenses by 42.1% through budget control and improved efficiency, resulting in a narrowed net loss of RMB9.7 million compared to RMB108.0 million in the previous year.